Daniel Cochrane

Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro

Meera G. Nair, Daniel Cochrane, Judith E. Allen · Immunology Letters · 2003 · 206 citations

Macrophage Biology, Inflammation, Novel Phenotype +13

Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112

Virginie Prod’homme, Daniel Sugrue, Richard J. Stanton et al. · Journal of General Virology · 2010 · 106 citations · Full text

Cell Surface Expression, Molecular Virology, Hcmv Genome +15

Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells

Margaret Kruse, C.H. Dark, Megan Aspden et al. · International Journal of Infectious Diseases · 2021 · 46 citations · Full text

Infection of mice with respiratory syncytial virus during neonatal life primes for enhanced antibody and T cell responses on secondary challenge

L Tasker, Ross Lindsay, Ben Clarke et al. · Clinical & Experimental Immunology · 2008 · 32 citations · Full text

Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies while Maintaining Biological Activity <i>In Vitro</i> and <i>In Vivo</i>

Nora Francini, Daniel Cochrane, Sam Illingworth et al. · Bioconjugate Chemistry · 2019 · 22 citations · Full text

Oncolytic Adenovirus Enadenotucirev, Neutralizing Antibodies, Engineering +18